Ashleigh R Tuite, Alison E Simmons, Monica Rudd, Alexandra Cernat, Gebremedhin B Gebretekle, Man Wah Yeung, April Killikelly, Winnie Siu, Sarah A Buchan, Nicholas Brousseau, Matthew Tunis
BACKGROUND: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the cost-effectiveness of different age cut-offs for RSV adult vaccination programs, with or without a focus on people with higher disease risk due to chronic medical conditions. METHODS: We developed a static individual-based model of medically attended RSV disease to compare alternative age-, medical risk-, and age-plus medical risk-based vaccination policies...
September 9, 2024: Canadian Medical Association Journal: CMAJ